ADRO Market Opportunity $90 Billion. Novel Approach,Favorable Safety Profile. LINK
Excitement Among Proof-of-Concept Drug Companies Could Spill Over Into This Lesser-Known Name
Excitement from proof-of-concept stage drug companies like Aduro Biotech ( ADRO ) or Receptos (NASDAQ: RCPT) could spill over into the lesser-known Sunshine Heart (NASDAQ: SSH), whose device is in a pivotal study for the treatment of late-stage heart failure - a disease with prognosis as poor as the most aggressive cancers and no effective treatment options. The market opportunity is perhaps as largeas ~$90 Billion.Part of the reason Aduro has performed amicably is that their approach to treating cancer is novel and potentially offers a favorable safety profile, particularly when compared to standard of care.
steal and thanks guys
The Fly On The Wall
UBS-Esperion's stock does not reflect the company's revenue opportunity, contended the analyst, who called the company one of the top takeover targets among small and medium biopharma companies. Peters set a $140 price target on the shares, but added that the stock could reach $225 or higher if all the risks facing ETC-1002 are overcome, and could jump to $300 if the company is acquired. WHAT'S NOTABLE: On March 6, Esperion reported that ETC-1002 had met its primary endpoints in a Phase 2b study. Specifically, the blood cholesterol level of patients taking the drug dropped significantly more than those taking placebos, the company reported. Other research firms issued upbeat notes following the study, as Credit Suisse raised its price target on the shares to $130 from $100 on March 6 after the datawas announced and Citi on March 27 assumed coverage of the stock with a Buy rating and hiked its price to $140.
Cramer Remix: From Friday
Abigail Stevenson | @A_StevensonCNBC
Friday, 20 Mar 2015 | 8:26 PM ET
Celladon Corp: "A Good Spec. I'm a Buyer, Willing to Go for it"
Biotech to see continued growth in 2015: HC Wainwright
by Mourad Haroutunian
Both Advaxis (NASDAQ:ADXS) has benefited from strong interest Marque Investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis
Do The DD FOLKS :
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
PRINCETON, N.J., Aug. 25, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's investigational anti PD-1 antibody, pembrolizumab.
Celladon Shares May Have Upside to $70
The developer of gene therapy for heart failure to announce pivotal trial results.
We are initiating coverage of Celladon with a Buy rating and target of $70.
The total annual cost of treating heart failure today is $39 billion in the U.S. alone. By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significance of CUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transaction, if results are promising for future success
Updates on Biotech Stocks Celladon Corporation ( CLDN )Top line data due out on Systolic Heart Faiure.They have FDA Fast Track and Breakthrough Therapy Designations. We think this stock could see $80.
Updates on Biotech Stocks Celladon Corporation ( CLDN )Top line data due out on Systolic Heart Faiure.They have FDA Fast Track and Breakthrough Therapy Designations. We think this stock couldsee $80.